Compound profile
Melanotan I (Afamelanotide)
Stronger clinical signalAlso known as: Afamelanotide · Scenesse · NDP-MSH precursor · MT-1
A linear analog of alpha-MSH that selectively activates the MC1R melanocortin receptor to stimulate melanin production. FDA-approved under the name afamelanotide (Scenesse) for a rare light-sensitivity disorder, though the compound sold in research and tanning circles as "Melanotan 1" is not the same regulated product.
Overview
Melanotan I was developed at the University of Arizona in the 1990s as one of the earliest synthetic analogs of alpha-melanocyte-stimulating hormone, engineered to be more selective and longer-lasting than the natural hormone. Where its cousin Melanotan II activates multiple melanocortin receptors and produces broader effects, including on appetite and sexual arousal, Melanotan I is more selective for MC1R, the receptor specifically responsible for triggering melanin production in skin cells.
That selectivity and a large clinical development program eventually led to real regulatory approval: under the name afamelanotide, marketed as Scenesse, it received European approval in 2014 and FDA approval in October 2019, specifically to increase pain-free light exposure in adults with erythropoietic protoporphyria, a rare genetic disorder that causes severe, immediate skin pain on sun exposure. It is administered as a bioresorbable implant placed under the skin by a clinician, not as a self-injected peptide.
The products sold online and in research-chemical or tanning-community channels as "Melanotan 1" are not the FDA-approved Scenesse implant. They are compounded or unregulated peptide preparations with no manufacturing oversight, sold specifically for cosmetic tanning, a use the approved drug was never developed or tested for in that population or delivery method.
Mechanism (plain language)
Selectively activates MC1R on melanocytes, triggering the same intracellular pathway alpha-MSH uses naturally to increase production of eumelanin, the darker, more UV-protective form of skin pigment.
How it works
Melanotan I binds MC1R on melanocytes, the pigment-producing cells in skin, activating a cAMP-driven signaling cascade that increases production of eumelanin, the photoprotective, darker-toned melanin pigment, as opposed to pheomelanin, the lighter, less UV-protective pigment. Because it is more selective for MC1R than Melanotan II, it produces less crossover activity at the MC3R and MC4R receptors responsible for Melanotan II's more wide-ranging effects on appetite and libido, though it is not perfectly selective and some off-target activity is still reported.
In the approved Scenesse formulation, the peptide is delivered from a slow-release implant placed under the skin of the abdomen, providing a steady, controlled dose over roughly two months, which is how the pivotal trials demonstrated increased pain-free sun tolerance in erythropoietic protoporphyria patients. Self-administered injectable products marketed for tanning use a completely different, unregulated dosing approach, with no controlled studies establishing safe or effective dosing for that use.
What research suggests
Two Phase 3 randomized, placebo-controlled trials support afamelanotide's approved indication, demonstrating meaningfully longer pain-free sun exposure in erythropoietic protoporphyria patients. There is no comparable controlled trial evidence for cosmetic tanning use of unregulated "Melanotan 1" products.
Reported benefits
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Increased pain-free sun exposure in EPP
Phase 3 trials reported a median of 69.4 hours of pain-free sun exposure with afamelanotide compared with 40.8 hours on placebo, the basis for its FDA approval.
More receptor-selective than Melanotan II
Its greater selectivity for MC1R over MC3R/MC4R is associated with less pronounced appetite and libido side effects compared with Melanotan II, though it is not entirely free of off-target activity.
Sustained, controlled dosing via implant
The approved delivery method, a bioresorbable subcutaneous implant, provides steady drug exposure over about 60 days under clinical administration, a very different exposure profile from self-injected products.
Uncertainties & risks
The approved product is indicated specifically for a rare light-sensitivity disorder and delivered via a clinician-placed implant, not for cosmetic tanning via self-injection. Products sold online as "Melanotan 1" for tanning are unregulated, have not been evaluated by the FDA for safety, purity, or potency, and their long-term effects from repeated off-label injection are not established by the trials that support the approved drug.
It is important to separate the well-studied, FDA-approved afamelanotide implant from the unregulated injectable products sold under the same informal name for tanning purposes, since the safety and efficacy data described in the approval trials do not transfer to a different population, dose, and delivery method. Melanin-stimulating peptides in general have raised dermatologic concerns, including case reports of new or changing moles, which is a particular concern for a mechanism that specifically activates pigment-producing cells; regular skin checks are a reasonable precaution regardless of source or intended use. The FDA and other regulators have specifically warned that unlicensed "Melanotan" products carry unknown risks precisely because they fall outside the manufacturing and quality controls that governed the approved drug's development.
Side effects
Commonly reported
- Nausea: Reported in Phase 3 trials of the approved implant
- Headache: Reported in Phase 3 trials
- Implant-site reaction: Related to the approved subcutaneous implant delivery method
- Skin darkening: The intended pharmacological effect, but can be cosmetically unwanted depending on context and degree
Reported in the cited literature, not a complete list, and not medical advice. Individual responses vary; consult a qualified professional.
STACKD study summaries
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Primary sources
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.